CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM
Guillaume Belthier, Zeinab Homayed, Fanny Grillet, Christophe Duperray, Julie Vendrell, Ilona Krol, Sophie Bravo, Jean-Christophe Boyer, Olivia Villeronce, Jihane Vitre-Boubaker, Diana Heaug-Wane, Francoise Macari-Fine, Jai Smith, Matthieu Merlot, Gerald Lossaint, Thibault Mazard, Fabienne Portales, Jerome Solassol, Marc Ychou, Nicola Aceto Show all
CANCERS | MDPI | Published : 2021
Circulating tumor cells (CTCs) are promising diagnostic and prognostic tools for clinical use. In several cancers, including colorectal and breast, the CTC load has been associated with a therapeutic response as well as progression-free and overall survival. However, counting and isolating CTCs remains sub-optimal because they are currently largely identified by epithelial markers such as EpCAM. New, complementary CTC surface markers are therefore urgently needed. We previously demonstrated that a splice variant of CD44, CD44 variable alternative exon 6 (CD44v6), is highly and specifically expressed by CTC cell lines derived from blood samples in colorectal cancer (CRC) patients. Two differe..View full abstract
Awarded by Grant INCa-DGOS-Inserm
Grant INCa-DGOS-Inserm 6045; region Languedoc-Roussillon for the Chercheur dAvenir Grant; la Ligue Contre le Cancer for funding G.B. and Z.H.